ACC

This channel contains news about the American College of Cardiology (ACC), including coverage of its annual meeting and links to recently released practice guidelines. The ACC is a leading resource for cardiology professionals, including all its subspecialties. 

GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.
Feature | Artificial Intelligence
AI Collaboration is Key to Unlock its Power in Cardiac Care

The digital transformation of healthcare is underway, but it will advance further and faster if key stakeholders work ...

Home June 10, 2021
Home
Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.
Feature | ACC | By Dave Fornell, Editor
Key Cardiology Technology Takeaways at ACC 2021

Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 Americ ...

Home June 08, 2021
Home
Two years ago a study raised concerns that paclitaxel-coated devices may cause increased mortality in peripheral artery disease patients. However, numerous studies now show there is no risk of increased mortality. The most recent study is the SAFE-PAD study presented at ACC.21.
News | Peripheral Artery Disease (PAD)
SAFE-PAD Study Shows No Safety Issues With Paclitaxel-coated Devices In Peripheral Artery Disease

June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...

Home June 07, 2021
Home
The 30-day outcomes from the TRISCEND study of the transfemoral Evoque tricuspid valve replacement system demonstrated technical feasibility and an acceptable safety profile, along with improvements in tricuspid regurgitation (TR) and symptoms in patients with clinically significant TR.
News | Structural Heart
Edwards LifeSciences Reports Positive Clinical Updates on its Transcatheter Mitral and Tricuspid Valves

June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company's transcatheter mitral and ...

Home June 07, 2021
Home
Rates of burnout pre- and peak COVID-19 pandemic increased across all members of the cardiology care team and was particularly striking among cardiovascular team members, which researchers said may be because they were more likely at the bedside as patients were dying. Among all cardiovascular clinicians – cardiologists, physician assistants, nurse practitioners, nurses, pharmacists and imaging technologists – half provided direct care to patients with COVID-19. #COVID19 #ACCCOVID
News | Coronavirus (COVID-19)
Burnout Rate Doubles For Cardiology Clinicians Amid COVID-19 Pandemic

June 7, 2021 — The COVID-19 pandemic has taken a significant toll on cardiovascular clinicians, many of whom provide ...

Home June 07, 2021
Home
GE Healthcare had integrated artificial intelligence algorithms into many of its device technologies. Recently the vendor introduced AI-enabled real-time automated ejection fraction measurements on its Venue Go point of care ultrasound system.
News
GE Healthcare and the ACC Join Forces to Advance AI in Cardiac Care

June 3, 2020 — GE Healthcare is collaborating with the American College of Cardiology (ACC) through support of and ...

Home June 03, 2021
Home
RAFT-AF study showed type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart  heart and atrial fibrillation. #ACC21 #ACC2021
News | Heart Failure
Type of Heart Failure May Influence Optimal Approach for AFib Rhythm Control Versus Rate Control Strategy

May 19, 2021 — Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on ...

Home May 19, 2021
Home
ECMO unit in use to support a severely ill patient at the University of Michigan. ECMO was shown to imporve survival and neuro outcomes in sudden cardiac arrest patients who do not respond to standard therapy.
Feature | Sudden Cardiac Arrest
ECMO Increased Survival in Refractory Out-of-Hospital Cardiac Arrest

May 19, 2021 — A subgroup of patients who experienced an out-of-hospital cardiac arrest (OHCA) that did not respond to ...

Home May 19, 2021
Home
The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams. #ACC21 #ACC2021
Feature | Coronavirus (COVID-19)
AI Derived Cardiac Echo Measurements Able to Predict COVID-19 Mortality

May 18, 2021 — Artificial intelligence (AI) derived heart measurements were able to predict COVID-19 (SARS-CoV-2) mortal ...

Home May 18, 2021
Home
The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients. #ACC21 #ACC2021 #GALACTICHF
News | Heart Failure
GALACTIC-HF Shows Omecamtiv Mecarbil Brings Greater Benefits for Severe Heart Failure

May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a ...

Home May 18, 2021
Home
Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21. #ACC #ACC21 #ACC2021
News | Coronavirus (COVID-19)
Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients

May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly ...

Home May 18, 2021
Home
This trial used a therapeutic hypothermia system that used balloon catheters filled with cooled saline, such as the Zoll Thermogard XP temperature management system. #ACC21 #ACC2021 #therapeutichypothermia
News | Sudden Cardiac Arrest
Lower Temperature Therapeutic Hypothermia Did Not Improve Outcomes After Cardiac Arrest

May 17, 2021 — In patients receiving therapeutic hypothermia after suffering out-of-hospital cardiac arrest, those who ...

Home May 17, 2021
Home
The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization. The findings from the VOYAGER PAD trial were presented at the American College of Cardiology (ACC) 2021 Scientific Session.
News | Peripheral Artery Disease (PAD)
Rivaroxaban Reduces First and Total Ischemic Events in Patients with Peripheral Artery Disease

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

Home May 17, 2021
Home
The FLOWER-MI trial presented at ACC 2021 found no benefit to FFR-guided PCI in STEMI with multi-vessel disease. #ACC21 #ACC2021 #FFR
News | FFR Technologies
No Benefit to FFR-guided PCI in STEMI Patients With Multi-Vessel Disease

May 17, 2021 — In patients who received a coronary stent for an ST-elevation myocardial infarction (STEMI) heart attack ...

Home May 17, 2021
Home
The Record Paradise RDN catheter uses a balloon catheter filled with water to cool the vessel wall as ultrasound-based ablation energy is delivered. It delivers a ring of ablative energy to a depth of 1-6 mm. Kirtane said it requires 2-3 sonications lasting 7 seconds each in each of the main renal arteries. #ACC21 #ACC2021 #RDN
Feature | Hypertension | By Dave Fornell, Editor
Renal Denervation Lowers Blood Pressure in Medication-Resistant Hypertension 

May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system ...

Home May 16, 2021
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now